AR030923A1 - Sal del enantiomero a del acido carboxilico de 7-cloro-4-(2-oxo-1-fenil-3-pirrolidiniliden)-1,2,3,4-tetrahidro-2-quinolina, forma cristalina, composicion farmaceutica, procedimiento de preparacion, uso en terapia - Google Patents

Sal del enantiomero a del acido carboxilico de 7-cloro-4-(2-oxo-1-fenil-3-pirrolidiniliden)-1,2,3,4-tetrahidro-2-quinolina, forma cristalina, composicion farmaceutica, procedimiento de preparacion, uso en terapia

Info

Publication number
AR030923A1
AR030923A1 ARP000106511A ARP000106511A AR030923A1 AR 030923 A1 AR030923 A1 AR 030923A1 AR P000106511 A ARP000106511 A AR P000106511A AR P000106511 A ARP000106511 A AR P000106511A AR 030923 A1 AR030923 A1 AR 030923A1
Authority
AR
Argentina
Prior art keywords
tetrahydro
oxo
chloro
therapy
salt
Prior art date
Application number
ARP000106511A
Other languages
English (en)
Original Assignee
Glaxo Wellcome Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome Spa filed Critical Glaxo Wellcome Spa
Publication of AR030923A1 publication Critical patent/AR030923A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Psychology (AREA)
  • Otolaryngology (AREA)

Abstract

Una sal del enantiomero A de ácido 7-cloro-4-(2-oxo-1-fenil-3-pirrolidiniliden)-1,2,3,4-tetrahidro-2-quinolin carboxílico de formula (1) o un solvato del mismo, procedimientos para su preparacion, composiciones farmacéuticas que lo contienen y su uso en la terapia y particularmente su uso como medicina para antagonizar los efectos de los aminoácidos excitadores en el complejo del receptor de NMDA. Es util en el tratamiento o prevencion del dano neurotoxico o enfermedades neurodegenerativas.
ARP000106511A 1999-12-08 2000-12-07 Sal del enantiomero a del acido carboxilico de 7-cloro-4-(2-oxo-1-fenil-3-pirrolidiniliden)-1,2,3,4-tetrahidro-2-quinolina, forma cristalina, composicion farmaceutica, procedimiento de preparacion, uso en terapia AR030923A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9929037.1A GB9929037D0 (en) 1999-12-08 1999-12-08 Heterocyclic derivatives

Publications (1)

Publication Number Publication Date
AR030923A1 true AR030923A1 (es) 2003-09-03

Family

ID=10865952

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000106511A AR030923A1 (es) 1999-12-08 2000-12-07 Sal del enantiomero a del acido carboxilico de 7-cloro-4-(2-oxo-1-fenil-3-pirrolidiniliden)-1,2,3,4-tetrahidro-2-quinolina, forma cristalina, composicion farmaceutica, procedimiento de preparacion, uso en terapia

Country Status (30)

Country Link
US (2) US6713491B2 (es)
EP (1) EP1237886B1 (es)
JP (1) JP4311901B2 (es)
KR (1) KR100788579B1 (es)
CN (1) CN1325488C (es)
AR (1) AR030923A1 (es)
AT (1) ATE323691T1 (es)
AU (1) AU769232B2 (es)
BR (1) BR0016235A (es)
CA (1) CA2393303C (es)
CO (1) CO5251474A1 (es)
CY (1) CY1106105T1 (es)
CZ (1) CZ301052B6 (es)
DE (1) DE60027461T2 (es)
DK (1) DK1237886T3 (es)
ES (1) ES2257343T3 (es)
GB (1) GB9929037D0 (es)
HK (1) HK1047436B (es)
HU (1) HUP0203650A3 (es)
IL (2) IL150010A0 (es)
MX (1) MXPA02005802A (es)
MY (1) MY129892A (es)
NO (1) NO323263B1 (es)
PL (1) PL356713A1 (es)
PT (1) PT1237886E (es)
TN (1) TNSN00240A1 (es)
TR (1) TR200201503T2 (es)
TW (1) TW524804B (es)
WO (1) WO2001042238A1 (es)
ZA (1) ZA200204492B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2523233C (en) * 2003-04-25 2012-03-20 Nippon Chemiphar Co., Ltd. Salt of (2s,3s)-3-[[(1s)-1-isobutoxymethyl-3-methylbutyl]carbamoyl]oxirane-2-carboxylic acid
GB0327912D0 (en) * 2003-12-02 2004-01-07 Glaxo Group Ltd Medicament
US7576216B2 (en) 2004-07-30 2009-08-18 Abbott Laboratories Preparation of pyridonecarboxylic acid antibacterials
PT3056492T (pt) 2004-10-08 2021-12-27 Abbvie Inc Sal de meglumina e formas cristalinas do mesmo de um fármaco (delafloxacina)
WO2006110815A1 (en) * 2005-04-11 2006-10-19 Abbott Laboratories Pharmaceutical compositions having improved dissolution profiles for poorly soluble drugs
HUE052128T2 (hu) * 2011-10-25 2021-04-28 Janssen Pharmaceutica Nv Eljárás az 1-(5,6-diklór-1H-benzo[d]imidazol-2-il)-1H-pirazol-4-karbonsav meglumin sója kristályainak elõállítására

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231102A (en) 1989-03-08 1993-07-27 Merck Sharp & Dohme, Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
US5529999A (en) 1994-03-04 1996-06-25 Eli Lilly And Company Antitumor compositions and methods of treatment
US6413959B1 (en) * 1995-04-14 2002-07-02 Boehringer Ingelheim Kg Method of treating depression with arylglycinamide derivatives
US5977136A (en) * 1995-09-29 1999-11-02 Glaxo Wellcome Spa Tetrahydroquinolines as NMDA antagonists
GB9617305D0 (en) 1996-08-17 1996-09-25 Glaxo Wellcome Spa Heterocyclic compounds
MY125037A (en) * 1998-06-10 2006-07-31 Glaxo Wellcome Spa 1,2,3,4 tetrahydroquinoline derivatives

Also Published As

Publication number Publication date
JP4311901B2 (ja) 2009-08-12
AU2006001A (en) 2001-06-18
TNSN00240A1 (en) 2002-05-30
HUP0203650A2 (hu) 2003-03-28
TW524804B (en) 2003-03-21
CN1325488C (zh) 2007-07-11
PT1237886E (pt) 2006-07-31
PL356713A1 (en) 2004-06-28
HK1047436B (zh) 2006-07-21
TR200201503T2 (tr) 2002-10-21
NO323263B1 (no) 2007-02-19
CZ301052B6 (cs) 2009-10-21
GB9929037D0 (en) 2000-02-02
ZA200204492B (en) 2004-06-30
WO2001042238A1 (en) 2001-06-14
CA2393303C (en) 2009-10-20
CO5251474A1 (es) 2003-02-28
CN1407980A (zh) 2003-04-02
KR100788579B1 (ko) 2007-12-26
ATE323691T1 (de) 2006-05-15
IL150010A0 (en) 2002-12-01
DK1237886T3 (da) 2006-08-14
US20030008899A1 (en) 2003-01-09
KR20020086854A (ko) 2002-11-20
DE60027461T2 (de) 2006-09-28
EP1237886B1 (en) 2006-04-19
CZ20021981A3 (cs) 2003-01-15
JP2003516403A (ja) 2003-05-13
DE60027461D1 (de) 2006-05-24
MXPA02005802A (es) 2004-08-12
CA2393303A1 (en) 2001-06-14
MY129892A (en) 2007-05-31
ES2257343T3 (es) 2006-08-01
US20040162313A1 (en) 2004-08-19
BR0016235A (pt) 2002-08-27
NO20022682D0 (no) 2002-06-06
HK1047436A1 (en) 2003-02-21
HUP0203650A3 (en) 2004-01-28
AU769232B2 (en) 2004-01-22
EP1237886A1 (en) 2002-09-11
IL150010A (en) 2009-09-01
US6943176B2 (en) 2005-09-13
NO20022682L (no) 2002-07-17
CY1106105T1 (el) 2011-06-08
US6713491B2 (en) 2004-03-30

Similar Documents

Publication Publication Date Title
AR033346A1 (es) Acido aminoalcano carboxilicos, un procedimiento para su preparacion, intermediarios, y el uso de los mismos para la manufactura de un medicamento
AR029011A1 (es) Tiazoles e imidazo[4,5-b]piridinas, un proceso para su produccion, una composicion farmaceutica y el uso de dicho compuesto para la fabricacion de un medicamento
EA200701913A1 (ru) Лечение статином, омега-3 жирными кислотами и их комбинированным продуктом
EA201101243A1 (ru) 3h-имидазо[4,5-c]пиридин-6-карбоксамиды в качестве противовоспалительных средств
HUP0203325A2 (hu) Biciklusos aminosavak, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
ECSP088404A (es) Nuevos derivados de imidazo[4,5-b]piridina como inhibidores de la glucógeno sintasa quinasa 3, para uso en el tratamiento de demencia y trastornos neurodegenerativos
RU2013121788A (ru) Ингибиторы репликации вич
HN2008001666A (es) Derivados acidos de cicloalquilamino
AR019853A1 (es) Derivado del acido 3-aril-2-hidroxipropionico, proceso e intermediario para su preparacion, formulaciones farmaceuticas, uso de dicho compuesto en laelaboracion de un medicamento, metodo para la profilaxis y/o tratamiento de trastornos clinicos asociados con la resistencia a la insulina, y formulaci
BRPI0409427A (pt) composto, uso do mesmo, composição farmacêutica, método de tratamento de um humano sofrendo de uma doença hiperproliferativa, e, processo para a preparação de um composto ou de um sal, éster ou pró-droga farmaceuticamente aceitáveis do mesmo
PE20030738A1 (es) Sales de acido succinico de 5,7,14-triazatetraciclo[10.3.1.02,11.04,9] -hexadeca-2(11),3,5,7,9-pentaeno y composiciones farmaceuticas de las mismas
SE9901573D0 (sv) New compounds
AR013079A1 (es) Derivados sustituidos de tetrahidrofurano-3-onas, de tetrahidropirano-3- onas y tetrahidrotiofen-3-onas, un procedimiento para su preparacion unacomposicion farmaceutica de un medicamento util como inhibidores de proteasas e intermediarios
UY29823A1 (es) Derivados sustituidos de 7-cloro-3h-imidazol-(4,5-b) piridina, composiciones farmacéuticas que los contienen, procesos para la preparación de los mismos y aplicaciones
DK0920865T3 (da) Farmaceutiske sammensætninger indeholdende norastemizol
PT97395A (pt) Processo para a preparacao de 2,9-di-substituidas-4h-pirido{1,2-a}-pirimidin-4-onas e de composicoes farmaceuticas que os contem
AR020226A1 (es) Compuestos para la inhibicion de la secrecion de acido gastrico, procesos para su preparacion, formulaciones farmaceuticas y uso de dichos compuestos parapreparar medicamentos
AR030923A1 (es) Sal del enantiomero a del acido carboxilico de 7-cloro-4-(2-oxo-1-fenil-3-pirrolidiniliden)-1,2,3,4-tetrahidro-2-quinolina, forma cristalina, composicion farmaceutica, procedimiento de preparacion, uso en terapia
IE842559L (en) Preparing 6-beta-halopenicillanic acid derivatives
AR005102A1 (es) Compuestos derivados de octahidro-pirrolo [1,2-a]-pirazina 2,7-sustituidos, composiciones farmaceuticas y uso de dichos compuestos para la fabricacion deun medicamento.
ECSP055673A (es) Derivados de 4-(3,5-dicianofenoxi) pirazol para el uso como moduladores de transcriptasa reversa en el tratamiento del vih
AR007369A1 (es) El uso de derivados carboxilados y un medicamento que contiene uno o mas de dichos derivados
DE2963010D1 (en) 3-chloro-6-hydroxy-5-methylbenzoic acid derivatives, corresponding pharmaceutical preparations, growth promoting compositions, the use of the compounds for promoting growth in certain animals and their manufacture
IL148739A0 (en) 4-benzylaminoquinoline conjugates with bile acid and their heteroanalogues, methods for producing the same, medicaments containing these compounds and their use
DE69412612D1 (de) Desoxyazaphospholipid-derivate mit inhibierender aktivität auf phospholipase

Legal Events

Date Code Title Description
FB Suspension of granting procedure